These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 33795387)
1. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants. Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116 [TBL] [Abstract][Full Text] [Related]
5. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma. Pathania AS; Chava H; Chaturvedi NK; Chava S; Byrareddy SN; Coulter DW; Challagundla KB Cell Death Dis; 2024 Jun; 15(6):428. PubMed ID: 38890285 [TBL] [Abstract][Full Text] [Related]
6. Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow. Manenq C; Lesesve JF; Dreumont N; Massin F; Salignac S; Mansuy L; Chastagner P; Latger-Cannard V; Broséus J Int J Lab Hematol; 2020 Feb; 42(1):52-60. PubMed ID: 31821742 [TBL] [Abstract][Full Text] [Related]
7. Flow cytometry as a diagnostic tool in neuroblastoma. Furlanetto G; Spagnol F; Alegretti AP; Farias MG; Soares VJ; Daudt LE; Loss JF; Scroferneker ML; Michalowski MB J Immunol Methods; 2021 Nov; 498():113135. PubMed ID: 34478717 [TBL] [Abstract][Full Text] [Related]
8. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567 [TBL] [Abstract][Full Text] [Related]
9. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy. Chen S; Zhan S; Ding S; Zhang Q; Xuan H; Zhang X; Cao L J Cancer Res Clin Oncol; 2023 Dec; 149(18):16609-16621. PubMed ID: 37715830 [TBL] [Abstract][Full Text] [Related]
10. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma]. Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207 [TBL] [Abstract][Full Text] [Related]
11. NR1D1-transactivated lncRNA NUTM2A-AS1 promotes chemoresistance and immune evasion in neuroblastoma via inhibiting B7-H3 degradation. Xiang T; Li Y; Liu G; Li X J Cell Mol Med; 2024 May; 28(10):e18360. PubMed ID: 38785199 [TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Multicolor Flow Cytometry and Immunohistochemistry for the Detection of Disseminated Tumor Cells. Szánthó E; Kárai B; Ivády G; Bedekovics J; Szegedi I; Petrás M; Ujj G; Ujfalusi A; Kiss C; Kappelmayer J; Hevessy Z Appl Immunohistochem Mol Morphol; 2018; 26(5):305-315. PubMed ID: 28426528 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of bone marrow lesions in children with neuroblastoma detected by flow cytometry]. Popov AM; Shorikov EV; Verzhditskaia TIu; Tsaur GA; Druĭ AE; Solodovnikov AG; Savel'ev LI; Fechina LG Vopr Onkol; 2014; 60(4):469-75. PubMed ID: 25552066 [TBL] [Abstract][Full Text] [Related]
14. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879 [TBL] [Abstract][Full Text] [Related]
15. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337 [TBL] [Abstract][Full Text] [Related]
16. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881 [TBL] [Abstract][Full Text] [Related]
17. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma. Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896 [TBL] [Abstract][Full Text] [Related]
18. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710 [TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3. Eichholz T; Heubach F; Arendt AM; Seitz C; Brecht IB; Ebinger M; Flaadt T; Süsskind D; Richter L; Hülsenbeck I; Zerweck L; Göricke S; Paulsen F; Dombrowski F; Flotho C; Schönberger S; Ketteler P; Schulte J; Lang P Cancer Immunol Immunother; 2024 Jan; 73(1):19. PubMed ID: 38240863 [TBL] [Abstract][Full Text] [Related]
20. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence. Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]